About US
Contact us
-
Despite sales slide, Bristol-Myers CEO nabs 15% raise to $17.2MBristol-Myers Squibb CEOLamberto Andreottigot a 15% raise last year. And that's on top of a 26% increase the year before. Andreotti's 2012 compensation package amounted to $17.2 million, up from $11.2013/3/27
-
InteRNA Technologies Secures Additional Equity Financing to Progress Lead Program for Melanoma TreatmentInteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investors2013/3/27
-
Novartis, Early copies of Sanofi's Aubagio could roil European MS marketTheEuropean Medicines Agency's drug-review committee has recommended approval for Sanofi's ($SNY) newmultiple sclerosistreatmentAubagio. But the EMA says it doesn't deserve "new active substance" stat2013/3/26
-
CoCo Therapeutics Ltd Announces the Appointment of its Clinical and Scientific Advisory GroupCoCo Therapeutics Ltd, a newly formed UK Biotechnology Company today announced the appointment to its Clinical and Scientific Advisory Group of Clive Ballard, Jonathan Corcoran, Roy Lobb, Andrew Wood2013/3/26
-
Titan's Probuphine could help FDA in its efforts to fight opioid abuseTheFDAis wrestling with a host of issues surrounding the highly addictive and often abusedopioidsand just recommended a drug that may provide some help in its effort. Yesterday an FDA advisory commit2013/3/25
-
New drug discovery company to focus on Alzheimer'sA new drug discovery company has been established to progress research into the development of new treatments for Alzheimer's disease. CoCo Therapeutics has been formed by King's College London, The2013/3/25
-
Novartis breast cancer drug Afinitor nixed by U.K. gatekeepersThe U.K.'s cost-effectiveness watchdog has turned awayAfinitorforbreast cancer. The Novartis ($NVS) drug doesn't offer enough value for the money, the National Institute for Health and Clinical Excel2013/3/22
-
Sanofi investors win class-action status in diet drug suitSanofi ($SNY)now faces an investor class action over its weight-loss drug Zimulti. And it may have Amgen ($AMGN) investors to thank. A few weeks after the U.S. Supreme Court cleared Amgen shareholder2013/3/22
-
Merck KGaA, Bristol-Myers plan joint assault on China's diabetes marketDiabetesis rampant inChina, and growing. And relatively few of the more than 90 million Chinese diabetics are treated. It's no wonder that pharma companies are piling into China, diabetes treatments2013/3/21
-
Sanofi manufacturing delays trigger TB drug shortageSanofi ($SNY) manufacturing delays have put itstuberculosisdrug Rifamate on the FDAshortagelist. The pill combines the antibiotic rifampin with isoniazid, a commonly used TB treatment that's been run2013/3/21